The New Delivery Strategy of Albumin Carrier Utilizing the Interaction with Albumin Receptors

Albumin, the most abundant protein in human serum, is applied to various diseases as a drug delivery carrier because of its superior blood retention, high biocompatibility, and a wide variety of drug binding abilities. Albumin is known to distribute widely in the blood and various interstitial fluid...

Full description

Saved in:
Bibliographic Details
Published inChemical & pharmaceutical bulletin Vol. 70; no. 5; pp. 330 - 333
Main Authors Ishima, Yu, Maruyama, Toru, Otagiri, Masaki, Chuang, Victor T. G., Ishida, Tatsuhiro
Format Journal Article
LanguageEnglish
Published Japan The Pharmaceutical Society of Japan 01.05.2022
Japan Science and Technology Agency
Subjects
Albumin
albumin receptor
Albumins
Biocompatibility
biodistribution
Blood
CD36 antigen
denaturation
Drug delivery
Drug Delivery Systems
Excipients
human serum albumin
Humans
Organs
Osteonectin
oxidation
Proteins
Receptors
Receptors, Albumin - metabolism
Recognition
Tissue Distribution
oxidation
biodistribution
denaturation
albumin receptor
human serum albumin
Online AccessGet full text

Cover

More Information
Summary:Albumin, the most abundant protein in human serum, is applied to various diseases as a drug delivery carrier because of its superior blood retention, high biocompatibility, and a wide variety of drug binding abilities. Albumin is known to distribute widely in the blood and various interstitial fluids and organs. Different albumin receptors skillfully regulate the distribution characteristics of albumin in the body. Albumin receptors are a group of diverse proteins, such as FcRn, gp60, gp18, megalin, cubilin, SPARC, and CD36. Their tissue distributions in vivo are unique, with different albumin’s recognition sites. Therefore, the distribution of albumin in vivo is ingeniously controlled by these multiple albumin receptors. Reevaluation of these albumin receptors opens up new possibilities for applying albumin as a drug delivery carrier. If the tissue distributions of albumin receptors were known and the albumin recognition site of the receptor was identified, organ-specific active targeting would be possible. In this review, we would like to scrutinize what is currently known and share information to develop next-generation albumin carriers that focus on interactions with albumin receptors.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0009-2363
1347-5223
DOI:10.1248/cpb.c21-01024